Catalyst

Slingshot members are tracking this event:

Neurocrine Projected to file IND for CRF Antagonist Compound in 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
NBIX

100%

Additional Information

Additional Relevant Details Neurocrine is investigating multiple CRF antagonist compounds in preclinical evaluations and anticipate filing an IND for at least 1 in 2016.
http://phoenix.corpo...
Additional Relevant Details Update on 14 Feb 2017: The Company has submitted an Investigational New Drug application with the FDA for its CRF receptor antagonist NBI-74788 to treat patients with classic congenital adrenal hyperplasia (CAH).
http://phoenix.corpo...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 14, 2017
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords International New Drug Application, Crf Antagonist Compound, Corticotropin-releasing Factor, Congenital Adrenal Hyperplasia